CA
NBIX icon

Clearstead Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Clearstead Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$306K Sell
2,319
-766
-25% -$102K ﹤0.01% 852
2025
Q4 		$438K Buy
3,085
+1,771
+135% +$257K 0.01% 694
2025
Q3 		$184K Buy
1,314
+582
+80% +$78.9K ﹤0.01% 900
2025
Q2 		$92K Buy
732
+376
+106% +$43.1K ﹤0.01% 1090
2025
Q1 		$39.4K Buy
356
+43
+14% +$5.45K ﹤0.01% 1231
2024
Q4 		$42.7K Buy
313
+5
+2% +$618 ﹤0.01% 1202
2024
Q3 		$35.5K Sell
308
-440
-59% -$60.3K ﹤0.01% 1281
2024
Q2 		$103K Buy
748
+285
+62% +$39.1K ﹤0.01% 992
2024
Q1 		$63K Sell
463
-45
-9% -$6.15K ﹤0.01% 712
2023
Q4 		$66.9K Sell
508
-552
-52% -$63.5K ﹤0.01% 675
2023
Q3 		$119K Buy
1,060
+583
+122% +$61.4K ﹤0.01% 684
2023
Q2 		$45K Buy
477
+247
+107% +$24.1K ﹤0.01% 747
2023
Q1 		$23.3K Buy
+230
New +$23.9K ﹤0.01% 820

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearstead Advisors's NBIX Position: Q1 2026 in Review

Clearstead Advisors reduced its Neurocrine Biosciences (NBIX) stake by 25% in Q1 2026, selling an estimated $102K and leaving 2,319 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Clearstead Advisors first reported a position in NBIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $438K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Clearstead Advisors held 2,319 shares of Neurocrine Biosciences worth $306K as of Q1 2026.
  • Clearstead Advisors sold 766 Neurocrine Biosciences shares in Q1 2026, an estimated $102K.
  • Neurocrine Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #852 holding.
  • Clearstead Advisors first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 13 quarters since.
  • Clearstead Advisors's Neurocrine Biosciences position peaked at $438K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.